Compile Data Set for Download or QSAR
Report error Found 108 Enz. Inhib. hit(s) with all data for entry = 11607
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632954BDBM632954(US20230348453, Compound C2 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632956BDBM632956(US20230348453, Compound C4 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632957BDBM632957(US20230348453, Compound C5 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632965BDBM632965(US20230348453, Compound B3 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 13216BDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632953BDBM632953(US20230348453, Compound C1 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632962BDBM632962(US20230348453, Compound C10 | US12172993, Compound...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632963BDBM632963(US20230348453, Compound C11 | US12172993, Compound...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632965BDBM632965(US20230348453, Compound B3 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632958BDBM632958(US20230348453, Compound C6 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632959BDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 13216BDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetSerine/threonine-protein kinase SIK1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 13216BDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632955BDBM632955(US20230348453, Compound C3 | US12172993, Compound ...)
Affinity DataIC50: 1.59nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632960BDBM632960(US20230348453, Compound C8 | US12172993, Compound ...)
Affinity DataIC50: 2.96nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 13216BDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 3.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632979BDBM632979(US20230348453, Compound D7 | US12172993, Compound ...)
Affinity DataIC50: 3.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632962BDBM632962(US20230348453, Compound C10 | US12172993, Compound...)
Affinity DataIC50: 4.30nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632963BDBM632963(US20230348453, Compound C11 | US12172993, Compound...)
Affinity DataIC50: 4.43nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632959BDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 5.02nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 13216BDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 6nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632961BDBM632961(US20230348453, Compound C9 | US12172993, Compound ...)
Affinity DataIC50: 6.44nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632967BDBM632967(US20230348453, Compound E2 | N-(4-chloro-2-fluorot...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632975BDBM632975(US20230348453, Compound E13 | N-(2-chloro-4- (difl...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632968BDBM632968(US20230348453, Compound E3 | N-(2-chloro-4-(fluoro...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632973BDBM632973(US20230348453, Compound E11 | N-(2-chloro-4-(fluor...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632971BDBM632971(US20230348453, Compound E9 | N-(2-chloro-4-(fluoro...)
Affinity DataIC50: 10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632978BDBM632978(US20230348453, Compound D1 | US12172993, Compound ...)
Affinity DataIC50: 12.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632981BDBM632981(US20230348453, Compound D9 | US12172993, Compound ...)
Affinity DataIC50: 12.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632981BDBM632981(US20230348453, Compound D9 | US12172993, Compound ...)
Affinity DataIC50: 12.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632953BDBM632953(US20230348453, Compound C1 | US12172993, Compound ...)
Affinity DataIC50: 13nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632959BDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 13.4nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632954BDBM632954(US20230348453, Compound C2 | US12172993, Compound ...)
Affinity DataIC50: 14.4nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632958BDBM632958(US20230348453, Compound C6 | US12172993, Compound ...)
Affinity DataIC50: 14.7nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632979BDBM632979(US20230348453, Compound D7 | US12172993, Compound ...)
Affinity DataIC50: 17.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632959BDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 17.7nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632956BDBM632956(US20230348453, Compound C4 | US12172993, Compound ...)
Affinity DataIC50: 17.7nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632969BDBM632969(US20230348453, Compound E4 | N-(2-chloro-4- (diflu...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632977BDBM632977(US20230348453, Compound E16 | N-(2-chloro-4- (difl...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632969BDBM632969(US20230348453, Compound E4 | N-(2-chloro-4- (diflu...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632975BDBM632975(US20230348453, Compound E13 | N-(2-chloro-4- (difl...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632976BDBM632976(US20230348453, Compound E15 | N-(4-chloro-2-fluoro...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632974BDBM632974(US20230348453, Compound E12 | N-(2-chloro-4-(fluor...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632959BDBM632959(US20230348453, Compound C7 | US12172993, Compound ...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632971BDBM632971(US20230348453, Compound E9 | N-(2-chloro-4-(fluoro...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632972BDBM632972(US20230348453, Compound E10 | N-(2-chloro-4-(fluor...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 13216BDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataIC50: 20nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632980BDBM632980(US20230348453, Compound D8 | US12172993, Compound ...)
Affinity DataIC50: 22.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632960BDBM632960(US20230348453, Compound C8 | US12172993, Compound ...)
Affinity DataIC50: 22.8nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Iomx Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 632961BDBM632961(US20230348453, Compound C9 | US12172993, Compound ...)
Affinity DataIC50: 27.4nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

Displayed 1 to 50 (of 108 total ) | Next | Last >>
Jump to: